This is a routine supply-chain partnership for a pre-revenue, pre-FDA-clearance company. No financial terms were disclosed, so there is no immediate revenue or cost read-through. Monitor for future purchase orders under the agreement and for progress in the SYMON clinical program (SYMON-II pivotal study) which would support a 510(k) submission.
Price Chart
Executive Summary
Bluejay Diagnostics entered into a manufacturing services agreement with Argonaut Manufacturing Services to establish U.S.-based production of its IL-6 test cartridges for the Symphony platform, moving away from overseas manufacturing. The agreement covers tech transfer, formulation, fill/finish, and QC release testing, with an estimated 14-18 week delivery timeline from purchase order receipt. No financial terms were disclosed, and the Symphony System remains an investigational device without FDA clearance.
Key Facts
- Agreement signed May 27, 2026 with Argonaut Manufacturing Services for IL-6 cartridge manufacturing
- Services include tech transfer, formulation, filling, finishing, QC testing, and distribution
- Estimated 14-18 week delivery from purchase order receipt
- Symphony System is an investigational device — no FDA clearance yet
- No financial terms (deal value, pricing, minimum commitments) disclosed in the filing
- Company has $2M market cap and 0% analyst bullish consensus
Financial Impact
No financial terms disclosed in the filing; deal value, pricing, and minimum purchase commitments are not specified
Risk Factors
- Symphony System has no FDA clearance — commercial manufacturing is contingent on regulatory approval
- No minimum purchase commitments disclosed — Argonaut may not generate meaningful revenue for Bluejay
- Company has $2M market cap with 0% analyst bullish consensus — high risk of capital constraints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 press releases from GlobeNewswire.
| Document | Accession Number |
|---|---|
| 8-K Filing (BJDX) — Batch item 1 | 0001213900-26-063767 |
| Document: ea0293118-8k_bluejay.htm | 0001213900-26-063767 |
| Document: ea029311801ex99-1.htm | press-3304952 |
| Document: 0001213900-26-063767-index-headers.html | press-3304952 |
| Document: 0001213900-26-063767-index.html | press-3304952 |
| Document: 0001213900-26-063767.txt | press-3304952 |
| PRESS-RELEASE Data (Synthetic) | press-3304952 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $0.8323 | awaiting T+20 | — | $0.5600 (−32.72%) |
Oct 6, 2026 20d ago | 8-K | $0.8107 | awaiting T+20 | — | $0.5600 (−30.92%) |
Aug 13, 2026 10w ago | 8-K | $1.06 | awaiting T+20 | — | $0.5600 (−47.17%) |
Aug 13, 2026 10w ago | Press Release | $1.06 | awaiting T+20 | — | $0.5600 (−47.17%) |
Jul 22, 2026 13w ago | 8-K | $1.14 $0.9393 | ▼ −17.61% | ▼ −20.91% | $0.5600 (−50.88%) |
Jul 13, 2026 15w ago | 3 | $1.22 $0.9872 | ▼ −19.08% | ▼ −22.27% | $0.5600 (−54.10%) |
Jul 10, 2026 15w ago | 3 | $1.45 $1.07 | ▼ −26.21% | ▼ −28.63% | $0.5600 (−61.38%) |
Jun 29, 2026 17w ago | EFFECT | $1.44 $1.03 | ▲ +28.47% | ▲ +28.19% | $0.5600 (+61.11%) |
Jun 17, 2026 18w ago | S-3 | $4.46 $1.30 | ▲ +70.85% | ▲ +71.39% | $0.5600 (+87.44%) |
Jun 9, 2026 19w ago | 8-K | $4.49 $1.40 | ▼ −68.82% | ▼ −72.44% | $0.5600 (−87.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers